<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4042">
  <stage>Registered</stage>
  <submitdate>19/04/2013</submitdate>
  <approvaldate>19/04/2013</approvaldate>
  <nctid>NCT01918215</nctid>
  <trial_identification>
    <studytitle>Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.</studytitle>
    <scientifictitle>Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction</scientifictitle>
    <utrn />
    <trialacronym>CMR_GUIDE</trialacronym>
    <secondaryid>CMRG-HF-1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <healthcondition>Left Ventricular Systolic Dysfunction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - ICD
Treatment: devices - ILR

Other: Device Implantation - A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR

No Intervention: Observational Registry - A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR


Treatment: devices: ICD


Treatment: devices: ILR


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Occurrence of Sudden Cardiac Death or Ventricular tachycardia leading to syncope</outcome>
      <timepoint>At any time till 36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Sudden Cardiac Death</outcome>
      <timepoint>At any time till 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Syncopal Ventricular Tachycardia</outcome>
      <timepoint>At any time till 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>At any time till 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>New York Heart Association Functional class, Quality of life assessed by Minnesota Living with Heart Failure Questionnaire</outcome>
      <timepoint>3, 6,12, 24, 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Heart failure related hospitalizations</outcome>
      <timepoint>At any time till 36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health economic evaluation cost</outcome>
      <timepoint>At end of study-36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age equal or greater than 18 years

          -  Patients with coronary artery disease (CAD) or non-ischemic cardiomyopathy (NICM) of
             the idiopathic, chronic post myocarditis or familial type.

          -  Left ventricular systolic impairment as defined by left ventricular ejection fraction
             36-50% by any current standard technique (echocardiogram, multiple gated acquisition
             scan (MUGA), angiography

          -  Able and willing to comply with all pre-, post- and follow-up testing, and
             requirements

          -  On maximum tolerated doses of ACE inhibitors (or Angiotensin and Receptor Blockers if
             intolerant of ACE) and Beta Blockers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. History of cardiac arrest or spontaneous or inducible sustained ventricular
             tachycardia unless within 48 hours of an acute MI

          2. Cardiomyopathy related to sarcoidosis

          3. Standard Cardiac Magnetic Resonance imaging contraindications (e.g. severe
             claustrophobia)

          4. Currently implanted permanent pacemaker and/or pacemaker/ICD lead

          5. Clinical indication for ICD or Pacemaker or cardiac resynchronisation therapy.

          6. CMR LVEF =35% or&gt;50%

          7. Severe renal insufficiency (eGFR&lt; 30mls/min/1.73m2)

          8. Recent Myocardial Infarction (MI) (&lt;40 days) or revascularization (&lt;90 days)

          9. New York Heart Association HF functional class IV at baseline

         10. . Conditions associated with life expectancy &lt;1 year

         11. Pregnancy or in females of child-bearing potential, the non-use of accepted forms of
             contraception</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1055</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>John Hunter Hospital - New Lambton</hospital>
    <hospital>Royal Brisbane &amp; Women's Hospital - Herston</hospital>
    <hospital>Princess Alexandra Hospital - Wolloongabba</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Lyell McEwin Hospital - Elizabeth Vale</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Northern Hospital - Epping</hospital>
    <hospital>St Vincent's Hospital - Fitzroy</hospital>
    <hospital>Austin Hospital - Heidelburg</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2305 - New Lambton</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4102 - Wolloongabba</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>5112 - Elizabeth Vale</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3076 - Epping</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3084 - Heidelburg</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Coburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Villingen-Schwenningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wurzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Clydebank</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leicester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Flinders University</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>South Australian Health and Medical Research Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Contemporary heart failure (HF) guidelines recommend insertion of a primary prevention
      implantable defibrillator (ICD) in patients with left ventricular ejection fraction less than
      35% (LVEF &lt; 35%) on maximally tolerated medical therapy. Nevertheless, there are a
      substantial number of HF patients who have LVEF&gt;35% and hence do not qualify for ICD, who
      succumb to sudden cardiac death (SCD). At present our tools to reliably risk stratify these
      patients with mild-moderate systolic dysfunction (LVEF 36-50%) are poor. It is likely that
      these patients have ventricular scar and/or replacement fibrosis as a substrate for their
      malignant arrhythmia. Cardiovascular magnetic resonance imaging (CMR) can reliably identify
      and quantify both ventricular scar (seen in Ischaemic cardiomyopathy, ICM) and replacement
      myocardial fibrosis (seen in Non-Ischemic Cardiomyopathy, NICM).

      Methods/Design: A multi-centre randomised controlled trial in which 428 patients with
      mild-moderate left-ventricular systolic dysfunction (either ICM or NICM) and ventricular
      scar/fibrosis on cardiovascular magnetic resonance are randomized to either ICD or
      implantable loop recorder (ILR) insertion and are followed up for 3 years.

      Potentially eligible patients will have a screening CMR and will be enrolled into the device
      arm of study based on the presence of any ventricular scar/fibrosis (CMR +). Patients who do
      not have ventricular scar/fibrosis will be followed up in an observational registry, and will
      not be randomised.

      In both the device and registry arms, we aim to enrol 700 patients in Australia and 355 in
      Europe.

      The primary hypothesis is that among patients with mild-moderate left ventricular systolic
      dysfunction, a routine CMR guided management strategy of ICD insertion is superior to a
      conservative strategy of standard care.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01918215</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Joseph B Selvanayagam, MBBS</name>
      <address>Flinders Medical Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Joseph B Selvanayagam, MBBS</name>
      <address />
      <phone>+61 8 8404 2195</phone>
      <fax />
      <email>joseph.selvanayagam@flinders.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>